SCHEMBL7005064

SCHEMBL7005064

Cn1cc(CC(C=O)C(=O)O)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRN P28799 1/20 0.39
SORT1 Q99523 1/20 0.39
OPRM1 P35372 2/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
GAA P10253 1/20 0.39
ALDH1A1 P00352 3/20 0.38
L3MBTL1 Q9Y468 3/20 0.36
HTT P42858 1/20 0.36
ACACB O00763 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
MAPK1 P28482 1/20 0.34
ERCC5 P28715 1/20 0.34
TSHR P16473 1/20 0.34
GRM2 Q14416 1/20 0.34
FNTA P49354 1/20 0.34
FNTB P49356 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7741685 0.84 MEN1 (0.41) GRNSORT1OPRM1SMN1; SMN2GAA
SCHEMBL7468812 0.82 TSHR (0.40) GAAALDH1A1L3MBTL1KMT2ATP53
SCHEMBL3470504 0.82 GRN (0.43) GRNSORT1OPRM1SMN1; SMN2GAA
SCHEMBL21879115 0.78 GRIA1 (0.49) GRNSORT1HSD17B10
SCHEMBL21946640 0.78 GRIA1 (0.49) GRNSORT1HSD17B10
SCHEMBL25353489 0.78 GRIA1 (0.49) GRNSORT1HSD17B10
SCHEMBL9889437 0.77 TP53 (0.42) GRNSORT1OPRM1SMN1; SMN2GAA
SCHEMBL18235690 0.76 SMN1; SMN2 (0.35) GRNSORT1OPRM1SMN1; SMN2GAA
SCHEMBL21197744 0.75 PPARA (0.41) GRNSORT1OPRM1SMN1; SMN2GAA
SCHEMBL25355540 0.75 GRN (0.48) GRNSORT1OPRM1SMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1028955-B1 PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SMITHKLINE BEECHAM PLC (GB) 2003-07-16 EP disclosed
US-20020120139-A1 Pyrimidinone compounds and pharmaceutical compositions containing them HICKEY DEIRDRE MARY BERNADETTE (GB) 2002-08-29 US disclosed
EP-1028955-A1 PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SmithKline Beecham p.l.c. (GB) 2000-08-23 EP disclosed
WO-1999024420-A1 PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SMITHKLINE BEECHAM PLC (GB) 1999-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120139-A1 Pyrimidinone compounds and pharmaceutical compositions containing them PLA2G7, PLA2G1B, PLA2G4C GRN 2502/4885SORT1 4179/4885OPRM1 4218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.